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Abstract
Objective. This study aims to generate evidence on intel-
lectual development disorders (IDD) in Mexico. Materials 
and methods. IDD disease burden will be estimated with 
a probabilistic model, using population-based surveys. Direct 
and indirect costs of catastrophic expenses of families with a 
member with an IDD will be evaluated. Genomic character-
ization of IDD will include: sequencing participant exomes 
and performing bioinformatics analyses to identify de novo 
or inherited variants through trio analysis; identifying genetic 
variants associated with IDD, and validating randomly selected 
variants by polymerase chain reaction (PCR) and sequencing 
or real-time quantitative PCR (qPCR). Delphi surveys will be 
done on best practices for IDD diagnosis and management. 
An external evaluation will employ qualitative case studies of 
two social and labor inclusion programs for people with IDD. 
Conclusions. The results will constitute scientific evidence 
for the design, promotion and evaluation of public policies, 
which are currently absent on IDD.
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Resumen
Objetivo. Esta investigación busca generar evidencia so-
bre trastornos del desarrollo intelectual (TDI) en México. 
Material y métodos. La carga de la enfermedad por TDI 
se estimará con un modelo probabilístico usando encuestas 
poblacionales. Se estimarán costos directos e indirectos de 
gastos catastróficos de familias con un integrante con TDI. La 
caracterización genómica de TDI incluirá secuenciar exomas, 
realizar análisis bioinformático para identificar variantes de 
novo o heredadas a través de análisis de tríos, identificar 
variantes genéticas asociadas con TDI, y validar variantes 
aleatoriamente seleccionadas con reacción en cadena de 
polimerasa y secuenciación o qPCR. Se harán encuestas 
Delphi sobre mejores prácticas de diagnóstico y manejo de 
TDI. Una evaluación externa empleará estudios cualitativos 
de caso de dos programas de inclusión social y laboral para 
personas con TDI. Conclusiones. Los resultados serán 
evidencia científica que podrá ser la base para el diseño, 
promoción y evaluación de políticas públicas, actualmente 
ausentes para TDI.
Palabras clave: trastornos del desarrollo intelectual; TDAH; 
trastorno autista; gasto; México
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The Intellectual development disorders (IDD) Mexico study will combine epidemiological, clinical, eco-
nomic and social science methods; the objective is to 
determine the true dimension of IDD as a public health 
problem in Mexico. The results of this study will consti-
tute scientific evidence that can be the basis in order to 
design, promote and evaluate public policies, which are 
currently absent from public policy on IDD. 
Intellectual developmental disorders
in Mexico: a public health perspective
According to the 2014 National Survey of Demographic 
Dynamics in Mexico1 there are approximately 2 million 
people under 18 years old with serious IDD. Moreover, 
according to the first disability screening performed in 
Ensanut 2012, there is a 15% increased risk of IDD in 
children under 9,2 in whom development should be 
evaluated through a comprehensive approach regarding 
their cognitive, emotional and motor abilities and func-
tioning in terms of social integration. IDD are a group of 
developmental conditions characterized by significant 
limitations in cognitive functions associated with learn-
ing abilities or disorders and adaptive behaviors. IDD, 
previously grouped under the term mental retardation, 
constitute a poorly studied public health problem in 
Mexico and Latin America, and their magnitude has 
not been quantified.3 Although the prevalence of IDD 
in children is not extremely high, its consequences 
can be devastating given the lifetime impairment of 
fundamental aspects of cognitive, motor and social 
functioning, as well as language impairments. Interven-
tions focused on prevention, rehabilitation, community 
integration and labor inclusion are essential. IDD are a 
forgotten public health problem that are absent from 
legislative, health, education and legal field policies, 
and they do not benefit from governmental strategies 
of social development and poverty reduction. The diag-
nostic criteria for IDD have been the subject of ongoing 
international discussion, and significant discrepancies 
persist regarding issues such as scales and weights. A 
relevant clinical criterion for the previous characteriza-
tion of IDD worldwide was their inclusion in the 10th 
version of the International Classification of Diseases.4 
In this document, IDD are predominantly related to 
mental retardation of unknown cause without associa-
tion to dysmorphism or physical anomalies. Currently, 
several experts believe that a definition of IDD includ-
ing not only intelligence quotient but also the adaptive 
abilities of people with this disability is more useful.5 
In addition to categorization by severity in terms of the 
intelligence quotient level, or development of adaptive 
abilities, IDD can also be grouped into syndromic IDD 
and non-syndromic IDD, although this distinction can 
be difficult and non-conclusive.6 
Quantification of the population impact 
and determinants of IDD
Over the last decade, the rights and needs of persons 
with disabilities have received renewed consideration 
under the global agenda on population health and 
development, with the 2006 UN Convention on the 
Rights of Persons with Disabilities (CRPD),7 and a new 
bio-psycho-social approach to understand disability, 
functioning and participation.8
 Within this paradigm shift, disability is understood 
as the result from the interaction between a person’s 
impairment and obstacles and barriers in the environ-
ment. Contextual obstacles include legal, structural and 
physical barriers as well as prevailing attitudes that 
prevent participation in society. The more obstacles 
there are the more disabled a person becomes.
 The availability of appropriate information, in-
cluding statistical and research data that enable policy 
formulation and implementation related to disability, 
has also been recognized as an obligation within the 
2006 convention. On the other hand, the agenda for the 
new Sustainable Development Goals requires the iden-
tification of the population experimenting functional 
difficulties and disability through censuses and surveys 
along data disaggregation according to key variables to 
address the barriers faced by persons with disabilities 
in exercising their rights.
 Within the spectrum of disabling conditions, 
persons with IDD face the most severe restrictions to 
participation. Adequate epidemiological approaches 
are essential to identify the population at risk of not 
participating, estimate the magnitude and factors 
associated with these restrictions and generate recom-
mendations of policies oriented at removing contextual 
barriers of all sorts.
The economic burden of IDD
Disability, whether physical or intellectual, is a condition 
that limits the interaction of a person with their environ-
ment and generates a series of economic and social costs 
that are assumed by the person that suffers from it, by 
their family and by society in general. These costs can 
be classified as direct and indirect. Some of these costs, 
as the World Report on Disability9 recently noted, could 
be reduced if barriers that prevent the adequate devel-
opment of the person with the disability are removed. 
Artículo originAl
696 salud pública de méxico / vol. 58, no. 6, noviembre-diciembre de 2016
Lazcano-Ponce E y col.
 Despite its importance, few studies have sought to 
quantify the economic burden associated with disability, 
even in developed countries. This lack of evidence is 
primarily a result of the limited scope of information 
available on the various components of the cost of dis-
ability, which adds to the limitations present in surveys 
and administrative records to properly operationalize a 
definition of disability.
 There are several components of cost related to dis-
ability. There are direct and indirect costs, private costs 
and public expenditure on action programs targeted to 
the population that suffers from disabilities. According 
to the classification of the World Health Organization,9 
direct costs can be grouped into two categories: the 
additional private cost that people with disabilities and 
their families must cover to ensure an acceptable stan-
dard of living that is comparable to people without this 
condition; and the cost that is covered by the govern-
ment, through public programs, in providing benefits 
to people with disabilities.
 Private costs are related to expenses associated with 
the demand for health services, purchase of medica-
tions and the use of other goods and services related 
to the care of the person with the disability; however, 
there are also indirect costs, both tangible and intan-
gible, related to this health condition. One of the main 
indirect costs is related to the loss of productivity and 
work time, both from the people with the disability and 
from family members who are involved in their care, 
whose employment status results are often affected. To 
a large extent, this loss of well-being, in the medium 
and long term, results from the lack of accumulation of 
human capital, which in the life course of the affected 
people translates into a lower education, a lower likeli-
hood of access to the job market and, in the absence of 
social protection mechanisms, a lack of access to health 
insurance, whether public or private. In the case of 
family members, costs are incurred by the reduction 
of working time or choice of occupations that allow 
flexibility to be able to care for the person with IDD. In 
some cases, the indirect costs also affect the education 
level of the people responsible for caring for the person 
with IDD. The few studies on the subject estimate that 
the aggregate economic impact due to disability may 
represent up to 6.7% of the GDP.10 In the case of IDD, a 
recent study documented that families absorb most of 
the economic burden, representing an opportunity cost 
of approximately 85%, even after discounting benefits 
received through social programs.11
 In Mexico, data from the 2010 Population Census 
show that people with at least some mental limita-
tions showed significant lags compared to the rest of 
the population in aspects such as coverage of medical 
insurance, employment status and educational at-
tainment. For literacy alone, it was found that ap-
proximately 50% of people 15 years and older with 
some mental limitations were illiterate.12 An analysis 
in Mexico’s poor population found that an inability to 
perform daily activities was associated with greater 
out-of-pocket expenses.13 
 Because of the economic and social involvement 
of IDD in the population’s wellbeing, it is important 
to estimate the costs of IDD in Mexico. Understanding 
how the cost varies in different population groups, 
its composition and trends in recent years constitute 
essential inputs to improve public policy instruments 
that address the problem such that they become genuine 
social protection mechanisms that maximize the popula-
tion’s general wellbeing. In sum, there is a great need 
to estimate the magnitude, composition, distribution 
and change over time of the economic burden that IDD 
represent in families in Mexico.
Genetic determinants of IDD
IDD, also known as intellectual disability (ID), can be 
caused by genetic or non-genetic factors; however, is 
estimated that genetic causes are present in more than 
50% of individuals with intellectual disability.14 Genetic 
causes of IDD can be chromosomic (e.g., Down Syn-
drome), recognizable genetic syndromes such as Fragile 
X, or innate errors in metabolism and current techniques 
allow genomic characterization. IDD represent a huge 
challenge for clinical geneticists in the search for molecu-
lar diagnosis because they are heterogeneous conditions; 
this can mean families are left without accurate genetic 
or reproductive counseling.
 In a classical view, considering syndromic ID, in-
dividuals present with one or multiple dysmorphisms, 
severe anomalies or co-morbidities in addition to ID. 
While non-syndromic ID and ID of unknown cause have 
intellectual disability as the sole clinical feature. How-
ever, ruling out the presence of more subtle physical 
dysmorphisms, neurological anomalies and psychiatric 
disorders can be challenging.15
 For example, it has been observed that IDD, co-
exist with autism spectrum disorders (ASD) in most 
patients.16 Around 25 and 70% of children with ASD 
have some level of ID,17 while at least 10% of individuals 
with ID have ASD. Additionally, it has been reported 
that both the ID and autism can coexist with attention 
deficit disorder (ADD, also known as attention deficit/
hyperactivity disorder or ADHD)16 or hyperkinetic 
disorders.4 Some studies have consistently shown high 
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rates of ADHD in children with ID and vice versa.18,19 
Besides, it has been estimated that around 14 and 78% 
of children with ASD also meet criteria for ADHD.20,21 
Coexistence of these disorders results in further dete-
rioration of cognitive, motor and social skills, further 
reducing quality of life of patients.
 In addition to the comorbidities described above, 
it has been reported that children and adolescents 
with ASD and ADHD show an increased frequency of 
overweight and obesity.22,23 There is also evidence that 
the prevalence of obesity and overweight is greater in 
adolescents with ID than those without.23 Recently, a 
chromosomal deletion associated with autism, ID and 
overweight/obesity was identified,24 suggesting that 
genetic factors have a role in disorders such as obesity 
in individuals with IDD.
 The genetic determinants of IDD are well recog-
nized in specific syndromic forms such as chromosomal 
anomalies and single gene disruptions that contribute 
significantly to these disorders. Trisomy 21 (Down syn-
drome), for example, is considered the most important 
chromosomal cause of syndromic ID while FMR1 gene 
mutations (Fragile X syndrome) are the most common 
cause of inherited syndromic ID.25,26
 On the other hand, progress in genetic research 
has allowed the identification of changes in genome 
at the level of a single nucleotide (SNV, single nucleo-
tide variation) and copy number (CNV copy number 
variation), either deletions or duplications of DNA, 
associated with ID of unknown cause.27-29 It has been 
observed that single nucleotide mutations or CNVs 
implicated in ID are also associated with ASD, suggest-
ing that genetic causes for IDD and ASD are similar.30 
CNVs for ADD also have been identified, and overlap 
with the variants identified in ID and autism has been 
reported.31-33 Together, these observations support 
the participation of similar molecular processes and 
point out the contribution of genetic component in the 
development of these disorders.
 Many groups have focused on identifying the spe-
cific genetic causes of ID and ASD. As a result, between 
400 and 700 genes have been associated with these con-
ditions, many of which converge on pathways involved 
in regulation of neuronal function.29,30,34-36 Particularly, 
it has been shown that most of the genes associated to 
ID and autism have a role in the control of formation 
and function of synapses.37,38 Interestingly, a biologi-
cal systems study indicates that there are up to 4 000 
genes that may contribute to neurodevelopmental and 
neuropsychiatric disorders39 suggesting that a large 
number of genes associated with disorders as ID and 
autism have not been identified yet.
 New genomic technologies such as chromosomal 
microarray (e.g. microarray-based comparative genomic 
hybridization (array CGH)) and massive sequencing 
have improved the discovery of genetic variants with 
an etiologic role in IDD and other neurodevelopmental 
disorders.40-43 Chromosomal microarray analysis has 
been routinely utilized as a first-tier genetic test in pa-
tients with non-syndromic ID (providing a molecular 
diagnosis in 10 to 20% of cases);28,44 however, in the last 
years, the usage of exome sequencing has raised because 
it has proved to have the potential to increase molecular 
diagnosis yield27,43,45,46
 The use of these genomic tools for a better un-
derstanding of the etiology of complex disorders such 
as IDD, including identification of genes, molecular 
mechanisms and pathways involved, is extremely 
important to provide a better diagnosis and treatment 
option, particularly in countries where these conditions 
are poorly studied, such as Mexico.
Materials and methods
This project is organized into two stages of work that 
include eight activities and their corresponding aca-
demic outputs (figure 1). The proposed development 
of a 24-month project is described below.
Systematic review of the literature
A protocol will be developed for the systematic extrac-
tion and classification of the available scientific literature 
in national and international databases on the subject 
of IDD in children under 10 years old. The identified 
literature will be classified from a quantitative and 
qualitative classification matrix in a previously designed 
Excel sheet, from which it will be possible to disaggre-
gate information identified in the obtained literature 
in terms of theoretical, clinical, methodological and 
epidemiological aspects of IDD reported in the extracted 
articles. A descriptive analysis of the data obtained will 
be performed in Stata version 13. 
Review and harmonization of databases
Potential data sources will be identified and reviewed 
to estimate the disease burden and quantify the popu-
lation impact and determinants of IDD. Data sources 
will be explored, and study periods, strata, sub-groups 
and weightings included in the designs and population 
representativeness will be determined. The following 
data sources are proposed for review:
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 I. National Survey on Perception of Disability 2010
 II. National Survey of Health and Nutrition 2012
 III. National Survey on Living Standards of House-
holds 2002/2005/2012
 IV. Survey for the Study of Global Aging and Adult 
Health 2009/2013
 V. Census of Schools, Teachers and Alumni of Basic 
and Special Education 2013
 VI. National Survey of Household Income and Expen-
ditures 2014 
 VII. National Survey of Boys, Girls and Women in 
Mexico 2015
 The methodology used for the identification and 
measurement of IDD and measurement instruments will 
be reviewed, and the data sources will be harmonized 
with respect to proxy variables of IDD, considering pos-
sible normalization, transformation or standardization 
of variables.
Estimation of disease burden
and quantification of population impact
and IDD determinants
To estimate the disease burden, quantify the population 
impact and identify the determinants of IDD, explor-
atory and descriptive analyses will be performed as 
follows: nationally, by entity and other relevant strati-
fied analyses, by socio-demographic variables, such as 
age, sex, indigenous condition by self-ascription, size 
of locality (rural, urban, metropolitan), household char-
acteristics, socio-demographic level by income deciles, 
Figure 1. Overview OF study scheme. the phases, activities and respective prOducts are described
The intellectual developmental disorders Mexico study:
situational diagnosis, burden, genomics and intervention proposal
PHASES
PRODUCTS
ACTIVITIES
Stage1 Stage2
Catastrophic 
expenditures in 
households. Exome data 
for the genomic study of 
IDD
Situational and 
epidemiological 
diagnosis of IDDs in 
Mexico 
Genomic 
characterization of 
IDD in Mexico
Evidence based 
recommendations for 
prevention and care 
programs for IDD 
Genomic study of 
IDD, sampling and 
sequencing 
exome
Estimation of 
economic burden 
associated with IDD 
Systematic 
literature review 
Review and 
harmonization of 
databases
Estimation of 
disease burden; 
quantication of 
the population 
impact and 
determinants of 
IDD 
Genomic study 
of IDD, 
identication of 
genetic variants
External evaluation 
of social and labor 
inclusion programs
Meeting of experts 
to generate 
consensus on the 
best practices and 
key competencies 
for the 
management of 
IDD 
5
4
5
1
2
3
6
47
4
8
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etc. The prevalence of IDD will be analyzed by birth 
year cohorts in population databases to evaluate the 
proportion of IDD cases throughout life to approximate 
a prevalence of cases not related to congenital cases 
and to estimate the number of years that an individual 
lives with an IDD. Finally, the disease burden of IDD in 
Mexico will be estimated from the prevalence of IDDs by 
the number of expected years that an individual will live 
with an IDD by the weight associated with disability47 to 
calculate the DALYs for IDD. All of the analyses will be 
performed in Stata version 13. The results will provide 
fundamental input to guide decision-making in related 
public policies.48
Estimation of economic burden
Given the economic and social involvement of mental 
disability on the wellbeing of the population, it is very 
important to estimate the costs of intellectual disability 
in Mexico. Knowing how the cost varies in different 
population groups, as well as composition and trend in 
recent years, constitutes a fundamental input to improve 
public policy instruments49 oriented towards addressing 
this problem, in such a way that they comprise authentic 
social protection mechanisms that maximize the general 
wellbeing of the population. Therefore, the objective of 
this component is to estimate the magnitude, composi-
tion, distribution and change over time of the economic 
burden that IDD represent in families in Mexico.
 A conceptual framework will be developed which 
takes into account the areas of family wellbeing affected 
by the presence of a member with IDD. This implies tak-
ing into account the activities that are carried out at the 
domestic and professional level in order to promote the 
family, social (or community) and work-related integra-
tion of the family member with IDD. This framework 
will structure the identification of mechanisms that 
cause additional economic burden related to having a 
family member with IDD. 
 The principal data source will be the National 
Survey of Household Income and Expenses (ENIGH, 
per the initials in Spanish) for 2010-2016. The ENIGH 
is the standard survey for determining the distribu-
tion, amount and structure of household income and 
expenses. It also gathers socio-demographic and work-
related data on household members, including those 
with an intellectual disability, and the time household 
members use in caregiving. This survey is bi-annual 
and the data collected is representative at the national 
level, for urban and rural areas, and for some years 
is representative at the state level. A strength of this 
survey is that, through the Socio-economic Condi-
tions Module, it is the official source for the multi-
dimensional measurement of poverty, which covers 
not just poverty in terms of income but also access to 
basic needs.
 The analysis will be done in the following stages:
 I. We will describe the expense and income profiles 
of households with a member with an IDD in com-
parison to homes without, and change over time. 
Analysis will focus especially on the existence of 
differences in: the level of certain expenses, income 
level and work-related characteristics of household 
members.
 II. Based on information on time use by household 
members taken from the National Survey on Time 
Use 2014 and data from the National Survey on 
Perception of Disability 2010, we will estimate the 
time spent by household members in the care of 
other members with an intellectual disability. Us-
ing the satellite counting of unremunerated work 
method, we will estimate the economic burden in 
homes related to this type of activities.49
 III. Using the methodology for the multi-dimensional 
measurement of poverty in Mexico we will estimate 
poverty in households that have a member with 
IDD.50 We will identify, through a matching tech-
nique, households with and without a member with 
IDD that share socio-demographic characteristics. 
The goal is to estimate what would be the level of 
poverty that homes would have if they did not have 
a member with IDD. Information for 2010, 2012, 
2014 and 2016 from the Socio-economic Condi-
tions Module will allow us to identify whether the 
poverty level of these households has changed in 
relative terms.
 IV. Once the income level has been calculated for 
households, we propose to estimate the level 
of economic equality associated with those that 
include a member with IDD. To this end we will 
stratify households by income deciles and use the 
Gini coefficient and the concentration coefficient to 
explore if the presence of a household member with 
IDD is distributed differently by household income 
level and if it is, estimate the inequality gap.
Genomic characterization of IDD
in México
The identification of genetic variants associated with 
IDD of unknown etiology in children, adolescents and 
young adults stratifying by ADHD and ASD (in chil-
dren and adolescents between 6 and 15 years old) and 
overweight/obesity (in those over 18 years old), will be 
carried out as described below.
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Study population
Participating subjects will be recruited from the Dr. Juan 
N. Navarro Children’s Psychiatric Hospital (HPIDJNN) 
of Mexico City and the Integral Training and Develop-
ment Center (CADI A. C.) of Mexico City. In case of 
healthy infants (controls) recruitment will be carry out 
in schools of Mexico State. Written informed consent 
will be obtained from the parents of children, adoles-
cents and young adults. Assent will also be obtained 
from all of the minors and young adults of appropriate 
development and with capacity to granting it. All proce-
dures using in this protocol will be approve by the IRB 
(Institutional Review Board) and the ethic committee of 
participating institutions.
 Triads of healthy parents and offspring (children 
and adolescents between 6-15 years old and young 
adults over 18 years old) with and without IDD of un-
known etiology will be recruited to form 5 groups and 
10 strata, as described below:
Stratification by ADHD and ASD
Group I- 10 triads of parents and a child under 15 years 
old without an IDD and without ASD
a) 5 triads with a child without an IDD, without ASD 
and without ADHD
b) 5 triads with a child without an IDD, without ASD 
and with ADHD
Group II- 10 triads of parents and a child under 15 years 
old with an IDD of unknown etiology without ASD
a) 5 triads with a child with an IDD, without ASD and 
without ADHD
b) 5 triads with a child with an IDD, without ASD and 
with ADHD
Group III- 10 triads of parents and a child under 15 years 
old without an IDD and with ASD
a) 5 triads with a child without an IDD, with ASD and 
without ADHD
b) 5 triads with a child without an IDD, with ASD and 
with ADHD
Group IV- 10 triads of parents and a child under 15 years 
old with an IDD of unknown etiology and with ASD
a) 5 triads with a child with an IDD, with ASD and 
without ADHD
b) 5 triads with a child with an IDD, with ASD and 
with ADHD
Stratification by overweight/obesity
Group V- 10 triads of parents and child older than 18 
with an IDD of unknown etiology and the absence of 
ASD and ADHD
a) 5 triads with a child with an IDD and without 
overweight/obesity 
b) 5 triads with a child with an IDD and with over-
weight/obesity
 The diagnostic algorithm for the evaluation of sub-
jects with IDD of unknown etiology and comorbidities 
is shown in figure 2.
 The basic inclusion criteria are as follows: 1) Triad 
consisting of a father, mother and a child between 6 and 
15 years (from HPIDJNN) or a child over 18 years old 
(from CADI), 2) Presumptive clinical diagnosis of the 
disorder suspected by a health or infant care professional, 
3) Formal diagnostic assessment realized by specialized 
physicians using the international criteria DSM-516 and 
CIE-10,4 4) Neurological evaluation, 5) Child or adoles-
cent with an Intelligence Quotient (IQ) under 70 for the 
triads with IDD alone or with a comorbidity. 
 The exclusion criteria are as follows: 1) Cases 
without a confirmed clinical diagnosis, which are not 
classified in the triad groups described previously, with 
a neurological evaluation which verifies a diagnosis of a 
defined etiology, 2) Cases with suspicion of syndromic 
IDD or autism spectrum disorder and cases with a 
familial aggregation of IDD, ADHD and ASD, 3) Cases 
with suspected inborn metabolism error, and 4) Cases 
with a positive diagnosis of fragile X syndrome. 
Clinical diagnosis
A clinical history will be done for patients request-
ing care for the first time. The mental health status of 
each person (child, adolescent or young adult) will be 
determined with a psychiatric evaluation. A formal 
diagnostic evaluation will be done using appropriate 
tools. To confirm or refute ADHD the Mini International 
Neuropsychiatric Interview for Children and Adoles-
cents (Minikid) will be used.51,52 To confirm or refute 
an IDD, IQ will be measured using the WISC-IV53 and 
for children not enrolled in school the Stanford-Binet.54 
The adaptive level will be evaluated with the Vineland 
II adaptive behavior scal55 and functioning with the 
WHO-DAS 2.0 questionnaire for disability evalua-
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tion.56 The Childhood Autism Rating Scale, Second 
Edition (CARS-2)57,58 will be used as well as the Autism 
Diagnostic Interview, Revised (ADI-R)59 to confirm or 
refute a disorder on the autism spectrum. In addition, 
a neurological evaluation will be done through evalua-
tion of eye movements, pupil reflexes, facial mimicking, 
hearing, ability to manipulate the soft palate, swal-
lowing, phonation and tongue movements. Trophism, 
tone and strength in the neck and the four limbs will be 
determined as well as tendon reflexes. Walking will be 
evaluated and abnormal movements described. Mental 
health specialists will carry out all evaluations. Results 
will be included in the patient’s clinical file and reported 
to the family.
 Cases without a confirmed clinical diagnosis as 
well as cases that are not classified in the previously 
described triads, and cases with a neurological evalu-
ation that verifies a defined etiology will be excluded. 
* Recruiting and evaluation of triads with children and adolescents 6-15 years of age will be carried out at the Children’s Psychiatric Hospital Dr. Juan N. Na-
varro (HPIDJNN) in Mexico City and recruitment and evaluation of triads of people over 18 years old will be done at the Integral training and development 
center (CADI) in Mexico State
‡ Formal diagnostic evaluation will be done through application of tools described in the section on clinical diagnosis
§ Metabolic screening will be done in children and adolescents with IDD or autism spectrum disorders, to exclude cases with inborn metabolism errors
IDD: Intellectual Developmental Disorders
ADHD: Attention Deficit Hyperactivity Disorder
ASD: Autism Spectrum Disorders
Figure 2. diagnOstic algOrithm FOr the evaluatiOn OF subjects with idd OF unknOwn etiOlOgy
Study population 
Clinical diagnosis
First selection lter
Metabolic screening
Third selection lter
Genomic analysis
Clinical genetic
diagnosis
Second selection lter
Fragile X screening
Fourth selection lter
Medical genetic assessment
 Clinical/dysmorphological examination
 Family history of IDD, ASD, ADHD
Metabolic screening test§
CGG repeats (Fragile X) 
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Recruitment in Hospital, Refe-
rence Center and School
 Primary care
 Clinical referral (pediatrics, psychology,  
 neurology, psychiatry, others)
 Infant care professionals
Excluded from the study:
 Cases without conrmed diagnosis or  
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Excluded from the study:
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Excluded from the study:
 Cases with specic genetic 
 diagnosis (fragile X syndrome)
 Genetic counseling
 Recommended clinical regime
 Specialized referral
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regime
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 Neurologic examination
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Participants who leave the study at this point will con-
tinue with their habitual clinical treatment regime. In the 
case of young adults with IDD, overweight and obesity 
will be defined according to standard cutoff points. 
NormaI weight as BMI= 18.5-24.9 kg/m2, overweight 
as BMI= 25.0-29.9 kg/m2, and obesity as BMI ≥ 30 kg/
m2.60 For the study, subjects with a BMI ≤ 20 (normal 
weight control group) and subjects with a BMI ≥ 25 
(overweight/obese group) will be selected.
Clinical genetic diagnosis
For analysis of family background, a history of IDD, 
ADHD and autism spectrum disorder will be explored. 
For patients with IDD or an autism spectrum disorder 
a dismorphological clinical evaluation will be done. 
Weight and height will be measured and cranial shape, 
eyebrows, eyeballs, nose, oral cavity, ears, neck, thorax, 
abdomen, genitals (if necessary) and upper and lower 
limbs will be examined. In cases with family aggrega-
tion or with multiple dismorphisms suggestive of a 
known chromosomic or monogenic syndrome will be 
excluded from the study. Participants excluded from 
the study at this time will receive genetic counseling, 
specific therapeutic recommendations and the corre-
sponding referrals.
Metabolic screening
Participants diagnosed with an autism spectrum disor-
der or IDD who continue in the study will have a 2 ml 
peripheral blood sample taking to perform metabolic 
screening. Cases with suspected inborn metabolism 
errors will be excluded, receive genetic counseling and 
therapeutic recommendations and care and the cor-
responding referrals.
Fragile X screening
A saliva sample will be obtained from each member of 
the father-mother-child triad with Oragene DNA Kit 
from DNA Genotek (Cat. OG-500). An aliquot of the 
saliva sample from each child will be sent to a special-
ized laboratory, which will test fragile X, by the method 
of quantifying the expansion of CGG repeat in the FMR1 
gene by PCR. The samples will be classified as: normal 
(<55 repeats), premutation (55-200) and full mutation 
(> 200). Cases that do not have normal results (positive 
for fragile X) will be excluded, receive genetic counsel-
ing and therapeutic recommendations and care and the 
corresponding referrals.
 In case of normal result (negative for fragile X 
chromosome) genomic DNA of the triad will be iso-
lated using the prepIT L2P kit from DNA Genotek 
(Cat. PTL2P5). Samples will be stored at -70 °C until 
exome sequencing is performed. A part of the genomic 
DNA from each participant will be preserved and if 
necessary used for experiments related to the research 
proposed. 
Exome sequencing and detection
of variants
For genomic characterization, the coding regions 
(exome) of the genome of each integrant of de 50 triads 
previously described will be analyzed, using 1-5 μg de 
DNA and the Nextera Rapid Capture Exome kits of the 
company Illumina (Cat. FC-140-1001, Cat. FC-140-1003). 
Each sample will be sequenced in the Illumina HiSeq 
2000 platform with a configuration that allows us to 
obtain paired readings of 100 bases and a yield of up to 
300 million readings per sequencing line. For this study, 
at least 1.5 G bases of information per individual will 
be generated to obtain a coverage of ~50X (considering 
that the size of the exome is 30 million bases). With 
this depth, it is possible to search for punctual variants 
(SNV) with high reliability in addition to searching for 
discrepancies in the number of copies that correspond 
to structural variants (CNV). After passing a quality 
control, alignment will be performed using the refer-
ence human genome and punctual variants will be 
searched for with the FreeBayes program.61 CNV will 
be searched for using the CNV-tools of Bioconductor62 
and CoNIFER program.63 A comparison will be made 
between individuals of each family (trio analysis) to 
identify de novo or inherited variants in offspring (figure 
3). Subsequently, a comparison will be performed from 
the variables identified in unrelated individuals with the 
same condition (10 previously described strata). With 
the intersection of these variants and by comparisons 
between groups with and without disorders, it will be 
possible to select those variants potentially associated 
with each disorder. A search in public databases such as 
dbsnp (http://www.ncbi.nlm.nih.gov/SNP/), OMIM 
(http://www.omim.org/) and other genomic projects 
will be performed, to identify which of these variants 
already has an assigned phenotype and the type of in-
heritance followed. Finally, those variants that do not 
have a characterization or associated phenotype in the 
databases, will be new variants for which a functional 
prediction (pathogenic impact) using PolyPhen264 and 
SIFT65 will be realized. The identified variants will be 
validated by PCR and Sanger sequencing or by qPCR. 
New variants will be candidates for future screenings 
in larger populations of people diagnosed with IDD to 
statistically validate the association.
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Summary of the evidence base and generation
of consensus on screening and diagnostic 
tools for IDD and on guidelines for social 
and labor inclusion programs for people 
with IDD
Through a realist synthesis of the evidence base and a 
two-round Delphi study with clinical experts, an up-
dated consensus will be reached on which tools to use 
for psychiatric diagnosis of IDD and screening for IDD 
for referral to services. The same process will be used 
with a wider group of stakeholders to reach a consensus 
on guidelines for services and supports aimed at social 
and labor inclusion of people with IDD. We will do a 
systematic search of: 1) tools for screening and diagnosis 
of IDD and 2) guidelines and literature about services 
and supports aimed at social and labor inclusion of 
people with IDD. Then, we will do a realist synthesis 
of each body of documents, develop questionnaires and 
use them in Delphi surveys of the opinions of expert 
stakeholders for each topic.
 A realist approach to a literature search and syn-
thesis takes into account that no one tool or program 
works the same way in every context,66 thus providing 
information about how the context influences the suc-
cess, quality and general functioning of tools, programs 
The circles in the upper part of the figure represent the different clinical conditions for the 10 strata described in the text. The individual genomic characteriza-
tion steps are shown in white letters. Steps in the typification include comparisons between individuals and between conditions and are shown in black letters. 
ADHD: Attention Deficit Hyperactivity Disorder
IDD: Intellectual Developmental Disorders
ASD: Autism Spectrum Disorders
* Subjects with normaI weight (BMI= 18.5-20.0 kg/m2) or subjects with overweight/obesity (BMI ≥ 25.0 kg/m2)
Figure 3. wOrking scheme FOr the detectiOn OF variants assOciated with idd OF unknOwn etiOlOgy
Children and adolescents (6-15 years) Youth > 18 years
Healthy ADHD IDD ASD ASDADHD
IDD
ADHD
IDD
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de novo and  inherited variants in ospring
Variants by condition 
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Variants by disorder
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Identication of SNVs y CNVs
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or interventions in general.67 A realist synthesis of the 
literature often seeks to identify an intervention’s con-
text, mechanism and outcome.68 Therefore, we will do 
a realist literature search and synthesis which seeks to 
identify effective patterns in terms of the context, the 
mechanism used and the outcome achieved through a 
specific tool, program or intervention.67
 We will search the diagnostic and screening tools 
on the one hand, and guidelines and literature about 
social and labor inclusion for people with IDD on the 
other. Both types of documents will be searched for sys-
tematically and we will use an additional snowballing 
approach, as recommended by the Cochrane Collabora-
tion Guidelines for systematic reviews.67,69 Snowballing 
implies that in addition to a systematic search, individu-
als identified as experts in the Mexican, Latin American 
and to some degree the global context in the field of 
diagnostic and screening tools, guidelines and literature 
about social and labor inclusion for people with IDD will 
be contacted by email to request recommendations for 
documents relevant to the literature search.67,68
 Systematic extraction of data will include assess-
ment of methodological quality.70,71 Technical aspects 
of tools for screening and diagnosis of IDD will be 
extracted into a database. Data from guidelines and 
literature about services and supports for social and 
labor inclusion of people with IDD will be extracted 
and classified into three categories: context-mechanism-
outcome (using a data analysis matrix based on these 
three categories, with coding to achieve content and 
thematic analysis).67 This data will be grouped under 
themes or domains in order to develop statements for 
the Delphi survey. After grouping into domains, we 
will operationalize the synthesis of the findings into 
specific statements, to potentially be included in the 
survey. Before formulating the final version of this 
survey, the statements will be reviewed (using qualita-
tive methods)72 by three types of stakeholders: service 
providers (professionals who provide support for 
social and work inclusion to people with IDD); family 
members of people with IDD and services users (people 
with IDD themselves).71 Individual interviews or focus 
groups will be used with service providers and family 
members to review statements, while the nominal group 
technique will be used with people with IDD.
 The nominal technique is a method for achieving 
consensus which is highly structured, uses very small 
groups, does not require literacy (is applied verbally) 
and focuses on a single, unambiguous question.73 This 
technique has been used with people with ID and with 
dementia.72,74 A nominal group discussion goes through 
four steps: 1.) generation of ideas by each individual; 
2.) one-by-one statement (taking turns) of ideas which 
are noted down immediately; 3.) structured and time-
limited discussion of the ideas; 4.) voting on consensus 
or agreement about ideas expressed.72
 The two different panels for the Delphi surveys on 
screening and diagnostic tools for IDD and on guide-
lines for services and supports aimed at social and labor 
inclusion of people with IDD will be recruited through 
purposeful sampling, including snowball sampling. The 
research team will generate the initial contact list; each 
panel may have overlap (participants in both panels). 
All potential participants on the list will be asked about 
other possible participants they would suggest (with a 
maximum of 2-3 suggestions each).72,75 Participants will 
be emailed a link to the survey for each round, where 
they will be able to register their level of agreement 
with names of diagnostic and screening tools or with 
statements about components of services and supports 
aimed at social and labor inclusion of people with IDD. 
They will also be able to make comments about each ele-
ment. There will be 2-3 iterations (subsequent surveys) 
that will report to participants the level of consensus in 
the previous stage of the survey.72,76,77
External evaluation of programs
for social and labor inclusion for people
with IDD in Mexico
The objective of this component of the study is to gen-
erate scientific evidence needed to develop evidence-
based policy aimed at promotion of independent living 
and social and labor inclusion programs for people 
with IDD, through the external evaluation of the actual 
implementation in Mexico of such guidelines.
 In order to evaluate the functioning of programs 
for social and labor inclusion for people with IDD in 
Mexico, we will do two qualitative case studies78,79 on 
actual implementation of such programs, one a program 
assumed to be a “best practice” and one a program as-
sumed to be “lower functioning” or with more problems 
and barriers impeding good practice. The two programs 
will be selected purposefully and each case study80-84 
will include the following:
• Review of program documents; 
• Individual interviews with program personnel; 
• Use of data from the nominal groups with service 
users (people with IDD), generated during the 
previous activity; 
• Observation of program functioning, which will be 
registered on checklists.
 Program documents will be analyzed through con-
tent analysis and traditional qualitative thematic analy-
705salud pública de méxico / vol. 58, no. 6, noviembre-diciembre de 2016
The IDD Mexico study Artículo originAl
sis.85-87 Individual interviews with program personnel 
and data from the nominal groups with service users 
(people with IDD), and checklists of observation will 
be analyzed through qualitative thematic analysis.88,89 
First, an intra-case analysis will be done of the data 
for each case study. Second, a comparative, inter-case 
analysis will be done comparing the two cases.90 The 
analysis will focus on generating scientific evidence for 
developing evidence-based policy aimed at promotion 
of independent living and social and labor inclusion 
programs for people with IDD.91-93
Discussion
IDD and ID in general have not been included in the 
public health agenda in Mexico, in terms of research, 
evidence-based public policy or the evaluation of public, 
charitable or private services offered to people with IDD 
and their families. This research project will generate 
scientific evidence around IDD in a variety of areas. 
Although there is survey data on disability in Mexico, 
recent surveys have yet to be analyzed with a specific 
focus on ID. Therefore, statistical data on the burden of 
IDD at the population level will be processed and pre-
sented in order to provide this type of epidemiological 
information. Little data exist about the catastrophic costs 
IDD may have for families and so the direct and indirect 
costs families must cover when one of their members 
has an IDD will be estimated. Genomic analysis is not 
generally carried out to achieve diagnosis of IDD in 
Mexico. This project will contribute with the genomic 
characterization of IDD, including the identification of 
de novo or inherited variants as well as validation of 
selected variants. Consensus is lacking in Mexico on 
best practices in terms of which tools should be used 
for diagnosing IDD and what type of services can help 
people with IDD achieve social and labor inclusion. 
Through a realist systematic review and Delphi sur-
veys, this project will contribute in this area as well. 
Another gap in the data is how such services for social 
and work-related inclusion are provided in Mexico, 
and this project will seek to generate evidence on this 
topic through qualitative case studies. There is much to 
be done in the field of IDD in Mexico and this research 
project proposes important first steps in a series of fields, 
using appropriate approaches for each.
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